Intranasal Esketamine Clinical Data – Implications for Patients and Clinicians
In this video, Dr Sanil Rege, consultant psychiatrist reviews the key clinical data for intranasal esketamine in the management of treatment-resistant depression including:
- the onset of action and impact on depression symptoms 24 hours after dosing
- 28-day response and remission rates
- sustained response and prevention of relapse
- safety and tolerability
Based on data from the TRANSFORM 2 and SUSTAIN 1 and SUSTAIN 2 studies, we discuss what these results contribute to clinical practice for both patients and clinicians.
Any topics in mental health you would like covered? We would love to hear from you! Get in touch by contacting us at firstname.lastname@example.org.